LRRK2 Kinase Pathway in Parkinson's Disease

LRRK2 Kinase Pathway in Parkinson's Disease

Overview

[LRRK2](/entities/lrrk2) (leucine-rich repeat kinase 2) is a large, multi-domain protein with both kinase and GTPase activity. Pathogenic mutations in [LRRK2](/entities/lrrk2) — particularly G2019S ( accounts for 5-6% of familial PD and 1-3% of sporadic PD) — cause hyperactivation of its kinase domain, leading to increased phosphorylation of downstream targets that disrupt multiple cellular processes including autophagy, lysosomal function, synaptic vesicle trafficking, and mitochondrial homeostasis[@izzard2024, @blauwendraat2020].

Protein Structure and Domains

[LRRK2](/entities/lrrk2) is a 2527-amino acid protein containing multiple functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| Armadillo repeats | N-terminal | Protein-protein interactions |
| Ankyrin repeats | N-terminal | Scaffold for complex formation |
| Leucine-rich repeats (LRR) | Residues 980-1250 | Protein interactions, regulatory |
| COR (C-terminal of Roc) | 1275-1505 | Dimerization, GTPase regulation |
| ROC (Roc domain) | 1510-1855 | GTP binding, hydrolyzes to GDP |
| ML (MAPKKK-like) | 1885-2000 | Kinase activity |
| Kinase domain | 2000-2150 | Phosphorylates substrates |
| WD40 repeats | C-terminal | Protein interactions |

Autoregulation

LRRK2 Kinase Pathway in Parkinson's Disease

Overview

[LRRK2](/entities/lrrk2) (leucine-rich repeat kinase 2) is a large, multi-domain protein with both kinase and GTPase activity. Pathogenic mutations in [LRRK2](/entities/lrrk2) — particularly G2019S ( accounts for 5-6% of familial PD and 1-3% of sporadic PD) — cause hyperactivation of its kinase domain, leading to increased phosphorylation of downstream targets that disrupt multiple cellular processes including autophagy, lysosomal function, synaptic vesicle trafficking, and mitochondrial homeostasis[@izzard2024, @blauwendraat2020].

Protein Structure and Domains

[LRRK2](/entities/lrrk2) is a 2527-amino acid protein containing multiple functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| Armadillo repeats | N-terminal | Protein-protein interactions |
| Ankyrin repeats | N-terminal | Scaffold for complex formation |
| Leucine-rich repeats (LRR) | Residues 980-1250 | Protein interactions, regulatory |
| COR (C-terminal of Roc) | 1275-1505 | Dimerization, GTPase regulation |
| ROC (Roc domain) | 1510-1855 | GTP binding, hydrolyzes to GDP |
| ML (MAPKKK-like) | 1885-2000 | Kinase activity |
| Kinase domain | 2000-2150 | Phosphorylates substrates |
| WD40 repeats | C-terminal | Protein interactions |

Autoregulation

The kinase activity of LRRK2 is tightly regulated by multiple mechanisms:

• GTP binding to the ROC domain stimulates kinase activity (GTP-bound = active)
• ROC domain dimerization is required for kinase activity
• Phosphorylation of LRRK2 at S910, S935, S955, S973 by other kinases primes LRRK2 for activity
• 14-3-3 protein binding to phosphorylated S935 maintains cytosolic localization

LRRK2 Mutations in PD

Common Pathogenic Mutations

| Mutation | Domain | Effect on Kinase Activity | Population Frequency |
|----------|--------|---------------------------|---------------------|
| G2019S | Kinase (activation loop) | Gain-of-function; 2-3x increase | 5-6% familial PD, 1-3% sporadic |
| R1441C/H/G | COR domain | Variable; affects GTPase | 1-2% familial PD |
| N1437H | COR domain | Gain-of-function | Rare |
| Y1699C | ROC domain | Variable | Rare |
| I2020T | Kinase (DFG motif) | Gain-of-function | <1% familial PD |

Mechanism of G2019S Hyperactivation

The G2019S mutation replaces glycine (small, flexible) with serine (polar, larger) in the DFG+1 position of the kinase activation loop. This structural change:

Downstream Targets and Phosphorylation Cascade

Key Substrates

LRRK2 phosphorylates multiple proteins involved in cellular homeostasis:

| Substrate | Function | Effect of LRRK2 Phosphorylation |
|-----------|----------|----------------------------------|
| Rab GTPases (Rab3, Rab5, Rab8, Rab10, Rab12, Rab29, Rab35, Rab43) | Vesicle trafficking | Alters trafficking kinetics, disrupts endosomal/lysosomal function |
| MNK1/2 | Translation regulation | Unknown functional consequence |
| ERK1/2 | MAPK signaling | Enhanced activation |
| Akt | Cell survival | Altered signaling |
| GSK3β | Tau phosphorylation | May increase tau pathology |
| CSNK1D | Casein kinase 1 delta | Altered circadian regulation |

Rab GTPase Phosphorylation — Key Mechanism

Phosphorylation of Rab GTPases by LRRK2 is the most functionally significant downstream effect of LRRK2 hyperactivity:

Cellular Pathways Affected by LRRK2 Hyperactivity

Autophagy-Lysosome Pathway

LRRK2 G2019S disrupts autophagy at multiple steps:

The convergence of LRRK2 hyperactivity and autophagy dysfunction provides a mechanistic link between LRRK2 mutations and the accumulation of alpha-synuclein aggregates.

Mitochondrial Function

LRRK2 mutations affect mitochondrial dynamics:

Synaptic Function

LRRK2 is highly expressed at synapses and regulates:

• Synaptic vesicle trafficking: Rab3 and Rab8 phosphorylation disrupts vesicle cycling
• Presynaptic release: Reduced dopamine release in LRRK2 G2019S models
• Postsynaptic signaling: Altered NMDA receptor trafficking
• Synaptic plasticity: Impaired LTP in LRRK2 mutant mice

Neuroimmune Function

Microglial LRRK2 regulates inflammatory responses:

• LRRK2 G2019S microglia show increased pro-inflammatory cytokine production
• Enhanced NF-κB pathway activation
• Increased reactive oxygen species (ROS) production
• TLR4-mediated responses are exaggerated

LRRK2 in Neurodegeneration

Alpha-Synuclein Connection

The LRRK2 pathway intersects with alpha-synuclein pathology in multiple ways:

Tau Connection

LRRK2 mutations and tau pathology frequently co-occur:

• LRRK2 G2019S carriers can have elevated tau in CSF
• Mouse models show increased tau phosphorylation with LRRK2 mutations
• LRRK2 phosphorylates GSK3β, which in turn phosphorylates tau
• The relationship may be bidirectional — tau pathology can also affect LRRK2 function

Clinical-Pathological Correlations

| LRRK2 Mutation | Alpha-Synuclein Pathology | Tau Pathology | Other |
|-----------------|--------------------------|---------------|-------|
| G2019S | 70-80% (Lewy bodies) | Variable | Some TDP-43 |
| R1441C/H | ~50-60% | Less common | — |
| N1437H | Variable | — | — |

Rab GTPase Phosphorylation and Pathophysiology

The phosphorylation of Rab GTPases by hyperactive LRRK2 is now recognized as a central mechanism driving neurodegeneration in LRRK2-linked PD[@greggio2024]. Rab GTPases function as molecular switches controlling vesicle trafficking, and their phosphorylation by LRRK2 alters their guanine nucleotide state, effector interactions, and subcellular localization.

Rab10 is the best-characterized LRRK2 substrate in neurons. Phosphorylation at T73 (in the switch I region) converts Rab10 to a state that preferentially binds its guanine nucleotide, preventing normal GDP-bound/GTP-bound cycling. This disrupts:

• Endosomal-lysosomal trafficking: Rab10 coordinates cargo delivery to lysosomes; phosphorylation blocks autophagosome-lysosome fusion
• Phagocytosis: In microglia, Rab10 phosphorylation enhances pro-inflammatory responses
• Synaptic vesicle recycling: Rab10 localizes to presynaptic terminals where it regulates vesicle endocytosis

Rab8a phosphorylation regulates primary cilium function and cell polarity. LRRK2 mutations disrupt ciliogenesis, which may affect neuronal development and repair.

Rab3 (multiple isoforms A, B, C, D) phosphorylation at presynaptic terminals disrupts synaptic vesicle release probability and replenishment kinetics. LRRK2 G2019S neurons show reduced dopamine release amplitude and increased release variability.

Clinical Trials and Drug Development {#clinical-trials}

The LRRK2 inhibitor DNL151 (also known as BIIB122, developed by Denali Therapeutics with Biogen) represents the most advanced LRRK2-targeted therapy. The Phase 1 study (NCT04056689) enrolled 172 healthy volunteers and demonstrated[@heaton2023, @dnl2024]:

| Finding | Result |
|---------|--------|
| Target engagement | Dose-dependent reduction in pS935 LRRK2 in peripheral blood mononuclear cells (PBMCs) |
| Biomarker response | >50% reduction in pRab10 at highest doses |
| Safety | Well-tolerated; no serious adverse events |
| Pharmacokinetics | BBB-penetrant; plasma half-life supports once-daily dosing |

The LIGHTHOUSE trial (NCT05348785) is a Phase 3, randomized, double-blind, placebo-controlled study evaluating BIIB122 in patients with PD who carry the LRRK2 G2019S mutation. Key details:

• Enrollment: ~400 participants with confirmed G2019S mutation and early-stage PD (Hoehn & Yahr 1-2)
• Primary endpoint: Change from baseline in MDS-UPDRS Part I (non-motor) + Part II (motor) + Part III (motor) total score at 24 months
• Secondary endpoints: Change in DaTscan imaging, CSF biomarkers (pS129 alpha-synuclein, neurofilament light chain), Montreal Cognitive Assessment
• Duration: 24-month treatment period with 30-day follow-up
• Start date: 2022; expected completion: 2026

Biomarker strategy for LRRK2 inhibitor trials:

| Biomarker | Source | Rationale | Status |
|-----------|--------|-----------|--------|
| pS935 LRRK2 | PBMCs | Direct measure of target engagement | Validated |
| pRab10 (T73) | PBMCs | Downstream pathway biomarker | Validated |
| pS129 alpha-synuclein | CSF | Disease modification signal | Exploratory |
| Neurofilament light chain (NfL) | CSF, blood | Neurodegeneration biomarker | Exploratory |
| Dopamine terminal density | DAT PET | Neuroprotection signal | Exploratory |

Genetic Validation and Patient Stratification

LRRK2 mutations provide strong genetic validation for this therapeutic approach[@paisan2019, @blauwendraat2020]:

• G2019S is the most common pathogenic LRRK2 mutation (5-6% of familial PD, 1-3% of idiopathic PD)
• R1441C/G/H mutations in the COR domain also cause PD with variable penetrance
• N1437H and Y1699C are rare pathogenic variants
• LRRK2 PD is phenotypically similar to idiopathic PD but may have less cognitive impairment early

• Genetic testing for LRRK2 mutations is now commercially available
• G2019S carriers can be identified pre-symptomatically for prevention trials
• Non-mutation carriers with elevated LRRK2 activity may also benefit (research use)

Autophagy-Lysosome Pathway Disruption

LRRK2 G2019S causes profound defects in the autophagy-lysosome pathway, a major mechanism of neurodegeneration[@bolognin2022]:

Autophagy initiation defects: LRRK2 phosphorylates components of the PI3K complex (VPS34, Beclin-1), reducing initiation of autophagosome formation.

Vesicle trafficking disruption: Rab10 and Rab8 phosphorylation by hyperactive LRRK2 blocks the trafficking of autophagosomes toward lysosomes. Live-cell imaging in patient iPSC-derived neurons shows stalled autophagosomes that fail to fuse with lysosomes.

Lysosomal dysfunction: LRRK2 G2019S neurons show reduced lysosomal acidification, decreased cathepsin activity, and impaired lysosomal calcium release. This creates a feedforward loop: impaired autophagy leads to aggregate accumulation, which further stresses the lysosomal system.

Mitophagy defects: LRRK2 phosphorylates Rab proteins that regulate PINK1/Parkin-mediated mitophagy. Mitochondria in LRRK2 G2019S neurons show reduced quality control, elevated reactive oxygen species (ROS), and membrane potential loss.

Synaptic Dysfunction in LRRK2 PD

Synaptic pathology is an early feature of LRRK2-associated PD:

• Presynaptic terminals: LRRK2 is highly enriched at synapses where it regulates vesicle release. G2019S mutations cause:
• Reduced dopamine release amplitude (60-70% of controls)
• Increased release variability and stochastic failures
• Impaired synaptic vesicle pool replenishment
• Altered synapsin I phosphorylation (a key regulator of vesicle mobilization)
• Postsynaptic changes: G2019S neurons show altered NMDA receptor trafficking, reduced PSD-95 expression, and impaired long-term potentiation (LTP) in mouse models.
• Electron microscopy: Post-mortem tissue from LRRK2 G2019S carriers shows reduced synaptic density and altered synaptic morphology in the substantia nigra.

Microglial LRRK2 and Neuroinflammation

Microglia express high levels of LRRK2, particularly in disease states:

• LRRK2 G2019S microglia show hyperinflammatory phenotypes in culture
• Increased pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) in response to LPS or alpha-synuclein
• Enhanced NF-κB pathway activation and elevated NADPH oxidase activity
• Reduced debris clearance capacity, impairing synaptic pruning and aggregate removal

Therapeutic Targeting of LRRK2

Kinase Inhibitors (Primary Approach)

| Compound | Company | Stage | Notes |
|---------|---------|-------|-------|
| DNL151 (BIIB122) | Denali/Biogen | Phase 3 (NCT05348785) | LRRK2 inhibitor, BBB-penetrant |
| BIIB122 | Denali/Biogen | Phase 3 | Same as DNL151 |
| JM-10 | The Michael J. Fox Foundation | Preclinical | CNS-penetrant |
| GZ-2199893 | GlaxoSmithKline | Preclinical | Early LRRK2 inhibitor |
| XL-142 | — | Preclinical | Selective inhibitor |

Key development: Denali's DNL151/BIIB122 completed Phase 1 showing dose-dependent reduction in pS935 LRRK2 (pharmacodynamic biomarker) with good tolerability. Phase 3 LIGHTHOUSE trial in G2019S carriers ongoing.

Rationale for Inhibition

Challenges with Inhibition

Other Therapeutic Approaches

| Approach | Mechanism | Status |
|---------|-----------|--------|
| ASO therapy | Reduce LRRK2 mRNA | Preclinical |
| Protein degraders | PROTAC for LRRK2 | Discovery |
| GTPase modulators | Enhance GTPase activity to reduce kinase | Preclinical |
| Rab-directed | Inhibit downstream Rab phosphorylation | Research |

Biomarkers

Pharmacodynamic Biomarkers

| Biomarker | Source | Response to Inhibition |
|-----------|--------|----------------------|
| pS935 LRRK2 | PBMCs, lymphocytes | Decreases with LRRK2 inhibitor |
| pRab10 (T73) | PBMCs, brain tissue | Decreases with inhibition |
| Total LRRK2 | PBMCs | Unchanged |
| pS129 alpha-synuclein | CSF | May decrease with sustained inhibition |

Diagnostic Biomarkers

• Imaging: DAT PET scans show dopamine terminal loss in LRRK2 PD
• CSF: Reduced alpha-synuclein, elevated tau in some carriers
• Blood: pS935 LRRK2 as potential diagnostic/therapeutic monitoring biomarker

Open Questions and Research Frontiers

References

[@walls2024]: [Structure and function of LRRK2 (2024)](https://doi.org/10.1042/BST20240345)